Literature DB >> 2088193

Intraprostatic distribution of lomefloxacin following multiple-dose administration.

J M Kovarik1, J A de Hond, I M Hoepelman, T Boon, J Verhoef.   

Abstract

The ability of lomefloxacin to penetrate and distribute within the human prostate was assessed in 20 patients undergoing elective prostate surgery (18 transurethral prostatic resections and 2 prostatectomies). Subjects were middle-aged to elderly (mean age +/- standard deviation, 69.8 +/- 8.2 years) with normal hepatic function and with creatinine clearances ranging from 35.8 to 141 ml/min/1.73 m2. Lomefloxacin was administered in 400-mg doses orally every 24 h. Its disposition was characterized following the third dose by obtaining multiple serum samples and intraoperative paired central zone and peripheral zone prostate tissue samples. Lomefloxacin concentrations were determined by a validated high-performance liquid chromatography method with fluorescence detection. Concentrations in serum during the perioperative period declined from 3.1 +/- 1.0 mg/liter (mean +/- standard deviation) at 1 h postdose to 2.3 +/- 0.7 mg/liter at 6 h postdose. The time of tissue extraction ranged from 0.1 to 7.1 h postdose. Intraoperative serum lomefloxacin concentrations ranged from 0.5 to 4.8 (median, 2.4) mg/liter, while prostate tissue concentrations ranged from 1.1 to 10.1 (median, 5.4) mg/kg of tissue for the central zone and 0.9 to 6.5 (median, 5.2) mg/kg for the peripheral zone. Intraindividual paired prostate concentrations (central zone versus peripheral zone) were not statistically different. The partition coefficient (ratio of concentration in prostate to concentration in serum) for the central zone was 2.2 +/- 0.6 (range, 1.2 to 3.1), and for the peripheral zone it was 2.1 +/- 0.7 (range, 1.2 to 4.2). Lomefloxacin exhibited good penetration into the human prostate with homogeneous intraprostatic distribution following multiple-dose administration.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2088193      PMCID: PMC172068          DOI: 10.1128/AAC.34.12.2398

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Quantitative bacterial tissue cultures from 209 prostatectomy specimens: findings and implications.

Authors:  J I Gorelick; L B Senterfit; E D Vaughan
Journal:  J Urol       Date:  1988-01       Impact factor: 7.450

2.  In vitro and in vivo activity of NY-198, a new difluorinated quinolone.

Authors:  T Hirose; E Okezaki; H Kato; Y Ito; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

Review 3.  Antimicrobial agents in transurethral prostatic resection.

Authors:  M Grabe
Journal:  J Urol       Date:  1987-08       Impact factor: 7.450

4.  Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses.

Authors:  P J Morrison; T G Mant; G T Norman; J Robinson; R L Kunka
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

5.  The prostate and prostatic urethra: a morphologic synthesis.

Authors:  J E McNeal
Journal:  J Urol       Date:  1972-06       Impact factor: 7.450

Review 6.  Prostatitis, prostatosis, and prostatodynia.

Authors:  S M Orland; P M Hanno; A J Wein
Journal:  Urology       Date:  1985-05       Impact factor: 2.649

7.  The penetration of antibiotics into the prostate in chronic bacterial prostatitis.

Authors:  M Barza; G Cuchural
Journal:  Eur J Clin Microbiol       Date:  1984-12       Impact factor: 3.267

8.  In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents.

Authors:  R Wise; J M Andrews; J P Ashby; R S Matthews
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

9.  In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones.

Authors:  N X Chin; A Novelli; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

10.  Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function.

Authors:  A Leroy; J P Fillastre; G Humbert
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

View more
  4 in total

Review 1.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 2.  Quinolones as a Potential Drug in Genitourinary Cancer Treatment-A Literature Review.

Authors:  Tomasz Kloskowski; Sylwia Frąckowiak; Jan Adamowicz; Kamil Szeliski; Marta Rasmus; Tomasz Drewa; Marta Pokrywczyńska
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

Review 3.  Lomefloxacin clinical pharmacokinetics.

Authors:  C D Freeman; D P Nicolau; P P Belliveau; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

4.  Penetration of orally administered prulifloxacin into human prostate tissue.

Authors:  Claudio Giberti; Fabrizio Gallo; Maria T Rosignoli; Alessandro Ruggieri; Simona Barattè; Rossella Picollo; Paolo Dionisio
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.